We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Synthetic Material Revitalizes Damaged Vocal Cords

By HospiMedica International staff writers
Posted on 01 Aug 2011
A new study describes a synthetic polymer that can mimic the viscoelastic properties of human vocal cords.

Researchers at Harvard University (Boston, MA, USA) and MIT (Cambridge, MA, USA), have been developing a modified form of polyethylene glycol 30 (PEG30) that mimics the viscoelastic properties of human vocal cords. More...
In laboratory tests, the vibration that results from blowing air on a vocal-fold model of the synthetic PEG30 is very similar to that seen in human vocal folds. Also, tests showed that PEG30 can restore vibration to stiff, nonvibrating vocal folds such as those seen in human patients suffering from vocal-fold scarring.

The researchers then tested the biocompatibility of the gel by injecting it into the healthy vocal folds of dogs. After four months, no significant inflammation was observed on micro-laryngoscopic examination. Magnetic resonance imaging (MRI) and histologic analyses revealed time-dependent resorption of the PEG30 hydrogel by phagocytosis, with minimal tissue reaction or fibrosis. The study describing the development of PEG30, as well as other medical applications that could be achieved by modifying the chemical properties of the PEG, were published in the March 2011 issue of the Annals of Otology, Rhinology & Laryngology.

“What we did differently is we looked at this as a mechanical problem that we need to solve,” said lead author Sandeep Karajanagi, PhD, a former MIT researcher. “We said, 'Let's not look at the scar itself as a problem, let's think of how we can improve the voice despite the presence of the scar tissue.”

The researchers are now working on developing a manufacturing process that will generate enough of the material, in high quality, for human trials. They are also working on developing methods for injecting the material at the right location to treat human vocal cords. The researchers have applied for a patent on the material and are working toward US Food and Drug Administration (FDA) approval; if approved for human use, the gel would likely have to be injected at least once every six months, because it eventually breaks down.

Related Links:

Harvard University




Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.